TOL Stock Overview
A biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Toleranzia AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.58 |
| 52 Week High | SEK 0.84 |
| 52 Week Low | SEK 0.34 |
| Beta | 1.43 |
| 11 Month Change | -10.46% |
| 3 Month Change | 3.93% |
| 1 Year Change | -12.87% |
| 33 Year Change | -57.83% |
| 5 Year Change | -91.69% |
| Change since IPO | -93.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| TOL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -2.7% | -6.1% | -0.6% |
| 1Y | -12.9% | 21.0% | 17.0% |
Return vs Industry: TOL underperformed the Swedish Biotechs industry which returned 21% over the past year.
Return vs Market: TOL underperformed the Swedish Market which returned 17% over the past year.
Price Volatility
| TOL volatility | |
|---|---|
| TOL Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: TOL has not had significant price volatility in the past 3 months.
Volatility Over Time: TOL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 10 | Charlotte Fribert | www.toleranzia.se |
Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease.
Toleranzia AB Fundamentals Summary
| TOL fundamental statistics | |
|---|---|
| Market cap | SEK 114.70m |
| Earnings (TTM) | -SEK 6.30m |
| Revenue (TTM) | SEK 45.66m |
2.5x
P/S Ratio-18.2x
P/E RatioIs TOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TOL income statement (TTM) | |
|---|---|
| Revenue | SEK 45.66m |
| Cost of Revenue | SEK 46.03m |
| Gross Profit | -SEK 375.00k |
| Other Expenses | SEK 5.92m |
| Earnings | -SEK 6.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -0.032 |
| Gross Margin | -0.82% |
| Net Profit Margin | -13.79% |
| Debt/Equity Ratio | 0% |
How did TOL perform over the long term?
See historical performance and comparison